Empowered Patient Podcast

Tim Moran, CEO, Motus GI talks about their focus on endoscopy solutions that improve clinical outcomes for patients facing a critical colonoscopy while in the hospital.  The Pure-Vu system developed by Motus GI is a disposable sleeve that fits on the top of their reusable scope to allow irrigation and suction evacuation.  This enhancement can save time by eliminating delays in conducting the colonoscopy as well as reducing costs and need for additional time in the hospital. @Motus_GI #colonoscopy MotusGI.com Download the transcript here

Greg Merril, CEO, Adaptive Phage Therapeutics describes useful viruses that host on and kill bacteria acting as nature's natural antibiotic.  Phage therapy actually predates antibiotics but recent research has enabled scientist to better identify which phage will have the desired impact on specific bacteria.  Greg talks about how modern phage therapy, drawing on a large collection of phage, might become the best way to treat recalcitrant, chronic infections where antibiotics have failed.  Greg's father Carl Merril spent the majority of his career at NIH working on basic research on phage beginning in the mid 1960s. #phagetherapy #phage #antibiotics #viruses APhage.com Download the transcript here.

Dr. Hartmut Ehrlich, CEO, Abivax  gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results.  Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases. @abivax #abivax  #inflammation #IBD #rheum Abivax.com Download the transcript here

Michelle Sexton Naturopathic Doctor is an assistant adjunct professor in the department of anesthesiology in the UCSD health system.  She also has a clinical naturopathic and holistic practice working with patients who are looking to understand the underlying cause of disease and to treat the cause rather than the symptom.  Drawing on her understanding of the endocannabinoid system, Michelle explains how THC, the primary compound of cannabis, can be effective for treating pain, seizures, and opioid addiction. #cannabis #endocannabinoid #painmanagement MSextonND.com Download the transcript here  

Jeff Wolf, CEO, Heat Biologics describes the vaccine platform Heat has developed originally for oncology and their licensing agreement with the University of Miami to use the same vaccine approach for NIH-funded studies against Zika, malaria, and HIV against the Coronavirus.  Their novel approach is using allogeneic off-the-shelf contained cell based therapy that delivers a potent cell protein called GP96 that secretes antigens to activate T cells to attack the virus. #Coronavirus #COVID19 HeatBio.com Download the transcript here

Jovan Stevovic, founder, Chino.io provides a window into the challenges of protecting health data, how the European Union is handling security and privacy of healthcare data, and the high standards set by the new GDPR regulation.  Jovan also addresses the need by researchers for population health data, why the European insurance companies are mandated to provide insurance to everyone and the need to educate all stakeholders involved in healthcare and health to protect against inside and outside invasion. @chino_API Chino.io Download the transcript here  

Monique Elwell, COO and Co-Founder, Storyvine shares insights about how big and small pharma, medical device developers, healthcare providers, health insurance companies and non-profits are using this guided video tool to capture authentic stories from patients which can then be used in telling a broader view of personal experiences.  Monique talks about how patients are being encouraged to share intimate, vulnerable moments to help educate researchers as well as those facing similar health challenges. @StoryvineInc Storyvine.com Download the transcript here

Dr. Yair Saperstein, co-founder and CEO, avoMD is also chief resident in the department of medicine in the New York City Health and Hospital system.  Yair talks about the innovative online tool avoMD is developing to provide relevant portions of guidelines so that doctors can get specific help with the clinical scenario at hand. Yair also explains they are creating an ecosystem that is editable by doctors and providing a way for best practices in hospitals to be more accessible with the goal of improving success at point of care. @avocadoDOC avoMD.io Download the transcript here.

Dr. Gil Van Bokkelen, founder and CEO, Athersys a clinical stage biotech company, talks about developing cell therapies and regenerative medicine as alternatives to conventional standards of medical intervention and treatment using their MultiStem cell therapy platform.  Gil explains how cell therapies work by providing multi-dimensional solutions and how regenerative medicine therapies differ from traditional pharmaceuticals or biologics designed to do one very specific thing.  He also talks about how MultiStem has shown dramatic impact on stroke victims and on acute respiratory distress syndrome and inflammation in the lungs and their related work with lung transplant centers. @Athersys #regenerativemedicine #ARDS Athersys.com Download the transcript here

Jack Stover, CEO, Interpace Biosciences describes the changing landscape of drug development with the introduction of genetic data, creation of advanced diagnostic tests for pancreatic, thyroid, lung and esophageal cancers, and the resulting implications for treatment plans.  He also explains their work with big pharma companies in the area of immuno-oncology to determine potential partnerships with other drug candidates. @InterpaceBIO #IDXG #immunooncology #cancer Interpace.com Download the transcript here

David Johnson, CEO and co-founder, GigaGen discusses the company's recombinant intravenous immunoglobulin (IVIG) therapy in development to treat patients with primary immune deficiencies and its potential to overcome limitations of current IVIG plasma-based therapies.  David describes how GigaGen's recombinant IVIG is not tied to plasma supplies and has the potential to provide a high purity, consistent and ultimately safer treatment alternative for patients in need. #primaryimmunedeficiency #IVIG #antibody #PolyclonalAntibodies @GigaGeninc GigaGen.com Download the entire transcript here Page 1 of the Interview with David Johnson GigaGen Karen Jagoda: Welcome to the EmpoweredPatientPodcast.com show. I'm Karen Jagoda, and my guest today is David Johnson. He's the CEO and co-founder of GigaGen, that's G-I-G-A G-E-N.com. And Dave is an inventor, he's an entrepreneur and is an expert in single cell immunology. And we're talking today about IVIG therapies for patients with primary immune deficiencies. And Dave, I

Dan Passeri, CEO, Cue Biopharma discusses their proprietary Immuno-STAT(TM) platform.  Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases.  The platform is designed to harness the body's intrinsic immune system response without the need for ex vivo manipulation.  Cue is currently conducting a Phase 1 study in HPV16-driven head and neck cancer and partnering with Merck to develop treatments for autoimmune diseases. #immunooncology #HNSCC #TCells @CueBiopharma CueBiopharma.com Download the entire transcript here Page 1 of Transcript Karen Jagoda: Welcome to the empoweredpatientpodcast.com show. I'm Karen Jagoda, and my guest today is Dan Passeri. He's the CEO of Cue Biopharma. That's cuebiopharma.com. And I recently talked with Anish Suri, who is the Chief Scientific Officer at Cue, and I thought it was such an interesting story that I thought it was also a good idea t

Dr. Arnold Saperstein, Chief Medical Officer, Cecelia Health talks about how they are empowering diabetics to manage their disease as well as overall healthcare using personalized human to human coaching based on an individual's background, age and specific needs.  Their mission is to address challenges of medication compliance, insuring patients understand the role of diet and nutrition, and working with patients to remove barriers to the effective use of technology to help control their conditions. @CeceliaHealth #diabetes #mobilehealth CeceliaHealth.com Download the transcript here

Kinnari Patel, Chief Operating Officer, Rocket Pharmaceuticals discusses how Rocket is focused on creating new options for patients contending with rare genetic diseases.  Rocket is advancing several gene therapies for rare pediatric diseases and Kinnari provides insights into how the company is tackling the unique challenges facing patients with rare diseases, their caregivers and the community at large.  This February 29th Rocket Pharma is hosting a Rare Disease Day event featuring patient discussions and opportunities for patients and families to engage with physicians and researchers in the NY healthcare community. @RocketPharma #RareDiseaseDay #RareDiseases #GeneticDisease #GeneTherapy #FanconiAnemia #DanonDisease #PatientFocused RocketPharma.com Download the transcript here

Renee Ryan, CEO, Cala Health talks about the focus of Cala on using electricity as medicine by developing wearable electronics to treat tremors in the hands of essential tremor patients.  Using neuromodulation technology, they have developed a device that includes a stimulator and a signal that is sent across two nerves in the wrist to read the frequency of the tremors and allow the patient to reduce tremors on demand. @calahealth #mobilehealth #essentialtremors #neuromodulation Cala Health Download the transcript here  

James Brown DVM, CEO, DURECT Corporation talks about how DURECT is advancing epigenetic therapies to treat alcoholic hepatitis and non-alcoholic steatohepatitis (NASH).  The company's lead asset, DUR-928 has demonstrated promising therapeutic potential treating patients with alcoholic hepatitis, a life-threatening acute liver disease caused by chronic alcohol abuse with no approved drugs for treatment.  Dr. Brown also talks about his background as a doctor of veterinary medicine and his goal to continue developing medicines that improve the lives of others. #AlcoholicHepatits #Epigenetic #NASH #LiverDisease DURECT.com Download the transcript here

Maria Picone, co-founder TREND.Community and Antonio Maltese, student with Huntington's Disease talk about the challenges of finding valid information about rare diseases, the value of community support in discovering novel approaches to treatments, providing evidence to pharmaceutical companies about little understood symptoms, and advocating for awareness about rare diseases particularly during Rare Disease week and Rare Disease Day February 29. #rarediseases #huntingtonsdisease HopeForHuntingtons.com TREND.Community Download the transcript here  

Brad Margus, CEO, Cerevance talks about discovering and developing novel therapies for central nervous system diseases using the Cerevance powerful NETSseq target discovery platform and their large collection of human brain tissue samples.  Brad explains why the brain is such a challenging organ to study and their efforts to understand brain cell loss in such diseases as Parkinson's and Alzheimer's. #brain #CNSdisorders #Parkinsons #Alzheimers #NETSseq Cevevance.com Download the transcript here

Brad Robinson, CEO, Predictive Technology Group talks about the company's work focusing on women's health and why they decided to focus on this neglected field that has significant unmet medical needs.  Brad discusses the importance of genetics in informing a woman's course of care.  Brad also talks about the company's subsidiaries Predictive Analytics, Predictive Laboratories, and Predictive Biotech and how the synergy between these entities is instrumental in helping women and their clinicians address endometriosis and other reproductive health concerns. #womenshealth #endometriosis #infertility #fertility #genetics #pregnancy #preeclampsia PredTechGroup.com Download the transcript here

Ulf Jungnelius MD, CEO, Isofol Medical discusses the increasing incidence of colorectal cancer as a global issue and the current challenges in treating this devastating disease.  Dr. Jungnelius also talks about the company's drug candidate, arfolitixorin, currently being studied in a global Phase 3 clinical trial with the aim to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer. #colorectalcancer #CRC #ColonCancer #MetastaticColorectalCancer #chemotherapy #FirstLineTreatment Isofolmedical.com Download the transcript here